Compare DSS & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSS | CYCN |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | 100 | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 7.6M |
| IPO Year | N/A | N/A |
| Metric | DSS | CYCN |
|---|---|---|
| Price | $0.96 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.5K | ★ 43.1K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,046,000.00 | $2,855,000.00 |
| Revenue This Year | $14.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.53 | ★ 1371.65 |
| 52 Week Low | $0.72 | $1.28 |
| 52 Week High | $1.90 | $6.25 |
| Indicator | DSS | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 32.47 |
| Support Level | $0.92 | $1.43 |
| Resistance Level | $0.99 | $1.51 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 58.62 | 0.69 |
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.